Expected ann...but always reassuring to hear it
ANP is sending all the right vibes to potential suitors / partners.
The count down to EMA trial start has started.
Once EMA official approval is in the bag, we'll hear about funding.
Hopefully the boffins at Sarepta, Roche and Pfizer are taking notice...
What is a rare disease P2B drug worth, ready for 'pivotal' trial in EMA...and possible platform potential for other inflammation indications?
Dr G's involvement on assessing the ATL1102 'new indications' data has obviously caused a delay!
What strategic insight has Dr Gittleson brought to the table, to warrant delaying the anns?
The force is strong on this one!
.
Ann: Manufacture of ATL1102 clinical supplies for Phase IIb trial, page-7
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
-0.001(1.37%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.5¢ | 7.2¢ | $66.67K | 916.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 127509 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.4¢ | 97444 | 1 |
View Market Depth
| Last trade - 15.23pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
-0.001 ( 2.70 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.3¢ | 7.2¢ | 1650 | ||
| Last updated 13.54pm 24/05/2024 ? | |||||
| PER (ASX) Chart |